The third batch of countries involved in these pharmaceutical enterprises (with list)

Pharmaceutical Network June 28th,the third batch of national collection, began to report the volume ofto the authoritative channels confirmed that Hunan Province has begun to the third batch of national collection of the volumeAccording to Seber Blue, there are 86 regulations in this report, involving nearly 300 pharmaceutical companies.In accordance with the requirements of national collection, as long as the evaluation of enterprises to reach 2 or more, plus the original research drugs, can form a full competitionTherefore, the selection of procurement varieties collected by the state should be produced within the scope of the evaluation of the two.According to Cypress Blue statistics, as of June 22, the number of enterprises rated reached 2 or more of the standard of 172In addition to the first two batches of national collection involved in 75 standards, that is, there are 97 product regulations are in line with the collection requirements.Among them, in the current volume of the product regulations, the largest number of enterprises rated for the hydrochloric acid metformin tablets, followed by the hydrochloric acid metformin slow release tablets (0.5g), catoply tablets (25mg).It was revealed that an online meeting of the countries concerned had been held on 18 June, at which the following important information was raised - training in the policy on reporting volumes and balance retention, and the completion of the report by 3 July.In addition, it has been reported that tomorrow, June 24, will convene a seminar of the relevant enterprisesThe signs appear that the third batch of national collection is getting closer and closer I believe that most pharmaceutical companies, has also been ready, ready to "fight." .　　Large varieties gathered, the competition is particularly fierce
as to whether the volume of varieties will eventually enter the procurement catalog, it is not yet certain, has been officialnotice However, from the variety of reported, there are still many bright spots .　　In the current amount of varieties, there are many market size of up to billions of large varieties each year .　　Metformin: 54.71 million the third batch of national collection, the highest attention is metformin .　　In the last round of national collection, the high-pitched metformin did not appear in the list of purchased varieties It is widely accepted in the industry that this may be related to the effects of nitrosamine impurity events If this national collection does not consider the impurity of API, metformin finally into the national collection catalog is a high probability event .　　In the domestic oral sugar-reducing drug market, metformin is second only to acapo sugar super-large varieties According to Minet.com, in 2019, the sales of metformin in public hospitals nationwide amounted to 5.471 billion yuan, with a market growth rate of 19.22% . According to the Data of the State Drug Administration, there are currently 124 approved articles of metformin tablets and 53 articles for the slow release of metformin tablets In terms of market pattern, according to the data of Thenet, Shi Guibao still occupies 47.33% of the market share of metformin, the remaining market, domestic generic sproducers are numerous, the competition is very fierce, and no domestic enterprises have a clear advantage . up to now, the number of companies rated for metformin hydrochloride and metformin hydrochloride has been evaluated If metformin successfully enters the third batch of national collection, one of the varieties will usher in a market reshuffle .　　The sandatin: 49.64
million speaking of shatatin, we should be no stranger, the time is earlier than metformin, nitrosamine impurities make this variety become the focus of public opinion .　　The "Sandan incident" began on June 15, 2018, Huahai Pharmaceuticals in the process of optimizing the evaluation of its production process of sandatan raw materials, found and identified one of the unknown impurities as NDMA, and then took the initiative to report to the National Drug Administration, the European Drug Administration, the United States FDA and other drug regulatory agencies .　　With the release on May 8th of the Technical Guidelines for the Study of Nitrosamines in Chemical Drugs in Central Asia (Trial), the "Sushatan Incident" has now come to an end After a round of turmoil, the smooth entry into the national collection, the same is facing severe competition .　　According to Minnet.com, the market size of The Shatan in 2019 will be RMB4,964 million, with a market growth rate of 4.89 percent It can be seen that although the market growth rate has declined slightly in 2018 and 2019 due to the impact of nitrosamines impurities events, the market size is still huge . in the competitive landscape, the market is still the original research company Novartis leading, occupying more than 50% of the market share Domestic enterprises by Changzhou four drugs, Hainan Huanglong, Guilin Huaxin, China Resources Sako leading . in the current reported varieties, A lot of enterprises have been evaluated by Yansatan, including Changzhou four drugs, Hunan Qianjin Xiangjiang, China Resources Sako, Lepu Heng- and Zhejiang Huahai If the shatan can finally enter the national collection catalog, not only the original research enterprise Novartis market will be affected, those who have not yet passed the consistency evaluation of the enterprise, will also usher in a new round of challenges .　　Onitrogen: 4.
089 billion onitrogin is the first atypical antipsychotic drug approved for long-term treatment of schizophrenia and the first atypical antipsychotic drug approved for the treatment of acute bipolar mania .　　According to Minnet data, in 2019 China's O nitrogen flat market size reached 4,089 million yuan, the market growth rate of 4.17% Although the growth rate of the market has slowed in recent years, but with its huge market base, tablets into the 4 plus 7, its collapse into the national collection, is also a matter of concern . at present, China's Ao nitrogen flat market pattern is different from the above-mentioned varieties Jiangsu Haussen accounted for the largest share of the market, more than 60%, in fact, Dr Reddy of India, Lilly, respectively, occupied 18.21%, 15.57% of the market, the three pharmaceutical companies accounted for a total of 97.68 percent of the market, the market is highly concentrated . if O nitrogen ping can enter the national collection, the current market pattern is expected to be broken, the original market accounted for a large proportion of enterprises, in order to keep the market is not eliminated, but also will face a round of inevitable price reduction crisis .　　Large varieties gathered, the competition is particularly fierce
in addition to metformin, shatatin, o nitrogen ping, the amount of varieties, there are many are very high market attention .　　For example, As the first national varieties to pick 4 plus 7 streams, Catopuri is also on the list of reports At present, the variety of 25mg reached 9 It is reported that in November 2019, Catopi was included in Hebei Province high blood pressure , diabetes outpatient drug centralized procurement, 25 mg specification price limit of 0.03 yuan / tablet If it is eventually included in the third batch of national collection, what level will its price fall to? .　　According to the data of The Inner Net, a total of 40 pharmaceutical companies won the bid in the 4-plus-7 pilot and 4-7 expansion of 61 products, all products in 2018 in the retail terminal market accounted for only 4.2%, overall, the current collection of varieties of winning enterprises share is relatively small, the impact on the retail market is small However, in the third batch of national lysing varieties, a number of highly known varieties in the retail market were added, such as dophenitone, silinaf, ammonia bromine, etc are also in the reported varieties .　　From this point of view, the future national collection is not only for hospital
market, will gradually spread to the retail market With the continuous advancement of the policy of 4 plus 7, the range of varieties continues to expand, regardless of whether the winning bid or not, the public hospital market for pharmaceutical companies will be more and more uncertain, the retail market is also more and more important to it .